Â
Overcoming Challenges in Treatment Intensification for Type 2 Diabetes
1.50 AMA PRA Category 1 Credits™
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Apply current data from clinical trials for A1C goal setting and individualization of treatment
- Recognize the importance of timely initiation of drug therapy including the early initiation of insulin in reducing the complications of type 2 diabetes
- Identify and implement strategies for overcoming the barriers to insulin initiation and medication adherence
- Describe interdisciplinary team and collaborative care approaches that can improve clinical outcomes
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.50 |
AMA PRA Category 1 Credits™ |
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
pmiCME designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Faculty and Editorial Board
Written By:
Silvio E. Inzucchi, MD, Professor of Medicine, Yale University School of Medicine, Director, Yale Diabetes Center, Clinical , Chief, Endocrinology, Yale-New Haven Hospital, New Haven, Connecticut
Edited By:
Alyce Kuklinski, NP, RN, Medical Director, pmiCME
Financial Disclosure Statement(s)
Dr. Inzucchi has served as a consultant for Boeringher-Ingelheim, Merck, and Takeda; as a speaker for Novo-Nordisk; and has served in a research study funded by Eli Lilly Co. on behalf of Yale University.
Ms Kuklinski has no financial relationships to disclose.
The content collaborators and planning committee at Horizon CME include Brian Lee, PharmD; Elizabeth Wilkerson, CHES; and Cara Williams, PharmD. Brian Lee, PharmD, Cara Williams, PharmD, and Elizabeth Wilkerson, CHES, have nothing to disclose.
Commercial Support:
This program is supported through an educational grant from sanofi-aventis U.S.
Instructions for Obtaining Credit:
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 credit AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Computer System Requirements:
Internet Explorer (version 7.0 and above) is the recommended browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A minimum screen resolution setting of 800 x 600 is recommended. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.
Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|